




Instance: composition-en-4be09f952ab4cdf2803ef423dc889e5c
InstanceOf: CompositionUvEpi
Title: "Composition for plenadren Package Leaflet"
Description:  "Composition for plenadren Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp4be09f952ab4cdf2803ef423dc889e5c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - plenadren"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Plenadren is and what it is used for</li>
<li>What you need to know before you take Plenadren</li>
<li>How to take Plenadren</li>
<li>Possible side effects</li>
<li>How to store Plenadren</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What plenadren is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What plenadren is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Plenadren contains a substance called hydrocortisone (sometimes called cortisol). Hydrocortisone is a 
glucocorticoid. It belongs to a group of medicines called corticosteroids. Glucocorticoids occur 
naturally in the body, and help to maintain your general health and well-being.
Plenadren is used in adults to treat a condition known as adrenal insufficiency, or cortisol deficiency. 
Adrenal insufficiency occurs when your adrenal glands (just above your kidneys) do not produce 
enough of the hormone cortisol. Patients suffering from long-term (chronic) adrenal insufficiency need 
a replacement therapy to survive.
Plenadren replaces the natural cortisol that is missing in adrenal insufficiency. The medicine delivers 
hydrocortisone to your body throughout the day. The cortisol levels in your blood increase rapidly to a 
maximum level, about 1 hour after taking the tablet in the morning, and then gradually decrease over 
the day with no or almost no cortisol level in the blood in the late evening and night when the levels 
should be low.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take plenadren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take plenadren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Do not take Plenadren</h2>
<p>if you are allergic to hydrocortisone or any of the other ingredients of this medicine (listed in 
section 6).
Warnings and precautions
Talk to your doctor or pharmacist before taking Plenadren
-
when you have a condition that makes you unable to take this medicine or when the medicine is 
not absorbed properly from your stomach. This may happen when you have stomach problems 
involving vomiting and/or diarrhoea. In these situations you should seek immediate medical 
care in order to receive treatment with injections of hydrocortisone and extra fluid 
administration.
-
if you have short-term or temporary illness such as infections, fever or situations causing a great 
amount of physical stress, such as surgery: your dose of hydrocortisone must be temporarily 
increased. Ask your doctor promptly for information on how you should handle these situations. 
If you are to have surgery, tell your doctor/dentist before the surgery that you are taking this 
medicine.
-
if for any other reason your general health is declining although you take your medicine as 
prescribed; seek immediate medical care.
-
if you have pheochromocytoma (a rare tumour of the adrenal glands). 
-
if your thyroid gland is not working normally tell your doctor since your dose of Plenadren may 
need to be adjusted.
Children and adolescents
Plenadren is not recommended for use in children and adolescents under 18 years old as it has not 
been studied in these patients.
Other medicines and Plenadren
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other 
medicines. During long term treatment with medicines treating infections (antibiotics) the dose of 
Plenadren may need adjustment by your doctor. If used with mifepristone, a treatment used to end a 
pregnancy, the effect of Plenadren may be reduced.
In addition, tell your doctor or pharmacist if you are using any of the following medicines, as the dose 
of Plenadren may need to be changed:</p>
<p>Phenytoin, carbamazepine and barbiturates - used to treat epilepsy</p>
<p>Rifampicin or rifabutin - used to treat tuberculosis</p>
<p>Ritonavir, efavirenz and nevirapine   used to treat HIV infection</p>
<p>St. John s wort - used to treat depression and other conditions</p>
<p>Ketoconazole, itraconazole, posaconazole and voriconazole - used to treat fungal infections</p>
<p>Erythromycin, telithromycin and clarithromycin - used to treat bacterial infections
Plenadren with food and drink
Do not take this medicine with grapefruit juice as the juice will conflict with the action of this 
medicine.
Pregnancy, breast-feeding and fertility
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine.
It is important that you continue treatment with Plenadren during pregnancy. Treatment in pregnant 
women with adrenal insufficiency is unlikely to cause any harmful effects on the mother and/or the 
baby. You should tell your doctor if you become pregnant as the dose of Plenadren may have to be 
adjusted.
You can breast-feed during Plenadren treatment. Hydrocortisone is excreted in breast milk. Doses of 
hydrocortisone used for replacement therapy are unlikely to have any effect on the child. However, 
talk to your doctor if you plan to breast-feed your baby.
Fertility in women with adrenal insufficiency or cortisol deficiency may be reduced. There is no 
indication that Plenadren, in doses used for replacement therapy, will have an effect on fertility.
Driving and using machines
This medicine may have minor influence on your ability to drive and use machines. Extreme tiredness 
and episodes of short-lasting dizziness (vertigo) have been reported. Poorly treated or untreated 
adrenal insufficiency reduces your ability to concentrate and will affect your ability to drive and use 
machines. It is therefore important to take this medicine as directed by your doctor when driving or 
using machines. If you are affected do not drive or use machines, until you have discussed the issue 
with your doctor.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take plenadren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take plenadren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. The dose is specific for you and is decided by your doctor.</p>
<p>When you wake up in the morning swallow Plenadren tablets whole with a glass of water at 
least 30 minutes before your breakfast, preferable between 6.00 am and 8.00 am in the morning.</p>
<p>You should preferably be in an upright position.</p>
<p>Do not divide, crush or chew the tablets. These tablets deliver hydrocortisone to your body 
throughout the day. If divided, crushed or chewed this may prevent the hydrocortisone dose in 
the tablet to cover the whole day, as it should.
The need for additional doses of Plenadren
During short-term or temporary illnesses such as infection, fever, or physical stress such as surgery you 
will need more hydrocortisone since the body cannot produce the additional amount of cortisol required 
in these situations. The dose must therefore be increased temporarily and your doctor may advise you to 
use other hydrocortisone tablets instead of, or in addition to Plenadren. Please discuss this with your 
doctor and follow the instructions on how to act in these situations.
The daily dose of Plenadren may have to be doubled or tripled in milder conditions such as a mild 
infection or stress. You should then take the second dose of this medicine 6 to 10 hours after the morning 
dose. If it is not enough to double the daily dose, you should take a third dose 6 to 10 hours after the 
second dose (6-10 hour intervals between doses). When your illness is over, return to your normal 
maintenance dose of this medicine.
The following signs and symptoms may suggest that you need to take additional doses of Plenadren or 
other forms of hydrocortisone: fatigue, weight loss, stomach discomfort, feeling light headed when you 
change from sitting to standing or dizziness when standing, darkening of your skin particularly skin 
creases and exposed areas. Contact your doctor promptly for advice if you notice any of these.
However, seek immediate medical help if you notice any of the following: severe weakness, fainting, 
abdominal pain, nausea, vomiting, back pain, confusion, reduced consciousness, delirium (very 
confused state).
If you take more Plenadren than you should
A too high dose of this medicine for more than a few days may be harmful to your health. Your blood 
pressure may increase, you may gain extra weight and your blood sugar may become too high. An 
increased dose is necessary occasionally in order for the body to cope with increased stress such as 
fever. If extra doses are needed frequently and regularly, you should contact your doctor for 
re-evaluation of your maintenance dose.
If you forget to take Plenadren
If you have forgotten to take your tablet in the morning, take it as soon as possible thereafter. Do not 
take a double dose to make up for a forgotten dose. If you experience any signs or symptoms listed in 
the section  The need for additional doses of Plenadren , contact your doctor immediately.
If you stop taking Plenadren
Stopping Plenadren may be life threatening. It is therefore important to continue taking this medicine
as prescribed by your doctor. Do not stop taking it without consulting your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
If you are changing treatment from other hydrocortisone tablets to Plenadren you may experience side 
effects during the first weeks. These side effects can be: stomach pain, feeling sick and tiredness. They 
will normally disappear with time, if not contact your doctor.
Side effects of this medicine are:
Very common (may affect more than 1 in 10 people)</p>
<p>Dizziness</p>
<p>Headache</p>
<p>Diarrhoea</p>
<p>Tiredness
Common (may affect up to 1 in 10 people)</p>
<p>Stomach pain/heartburn, feeling sick or nauseated</p>
<p>Pain in the joints</p>
<p>Rash</p>
<p>Itchiness
Additional side effects have been reported for other hydrocortisone medicines. These medicines have 
also been given for other indications than adrenal insufficiency replacement therapy, often in higher 
doses. Frequencies of these possible side effects are not known (frequency cannot be estimated from 
the available data). Talk to your doctor if you experience any of these side effects:</p>
<p>More prone to infection</p>
<p>Diabetes or problems with blood sugar levels (shown in blood tests)</p>
<p>Salt and water retention causing swelling and raised blood pressure (shown on medical 
examination) and low potassium level in the blood</p>
<p>Mood changes such as feelings of overexcitement or losing touch with reality</p>
<p>Difficulty sleeping</p>
<p>Raised pressure in the eye (glaucoma), clouding of the lens in the eye (cataract)</p>
<p>Heartburn, aggravation of any existing stomach ulcer</p>
<p>Weakening of the bones - this may cause bone fractures</p>
<p>Stretch marks, bruising, acne-like rash, excessive growth of facial hair, slow wound healing.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store plenadren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store plenadren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle label and carton after EXP. 
The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>What Plenadren contains</h2>
<p>The active substance is hydrocortisone.
Plenadren 5 mg: Each modified-release tablet contains 5 mg of hydrocortisone.
Plenadren 20 mg: Each modified-release tablet contains 20 mg of hydrocortisone.
-
The other ingredients are hypromellose, microcrystalline cellulose, pregelatinised starch
(maize), colloidal anhydrous silica and magnesium stearate. The coating system is a mixture of 
macrogol (3350), polyvinyl alcohol, talc and titanium oxide (E171). The 5 mg tablets also 
contain red iron oxide (E172), yellow iron oxide (E172) and black iron oxide (E172).
What Plenadren looks like and contents of the pack
The modified-release tablets are round (diameter 8 mm) and convex.
Plenadren 5 mg: the tablets are pink.
Plenadren 20 mg: the tablets are white.
Plenadren comes in bottles with a screw cap containing 50 tablets.
Pack sizes:
Carton containing one bottle of 50 modified-release tablets.
Carton containing 2 bottles of 50 modified-release tablets (100 tablets).
Not all pack sizes may be available in your country.
Marketing Authorisation Holder and Manufacturer
Marketing Authorisation Holder
Takeda Pharmaceuticals International AG Ireland Branch 
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 HWIreland
Manufacturer
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza 
50-58 Baggot Street Lower 
Dublin 2
D02 HWIreland
Shire Pharmaceuticals Ireland Limited
Block 2 &amp; 3 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
Ireland
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
Takeda Belgium NV
T l/Tel: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 medinfoEMEA@takeda.com</p>
<p>.: +359 2 958 27 medinfoEMEA@takeda.com 
Luxembourg/Luxemburg
Takeda Belgium NV
T l/Tel: +32 2 464 06 medinfoEMEA@takeda.com
 esk  republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 medinfoEMEA@takeda.com
Magyarorsz g
Takeda Pharma Kft.
Tel.: +36 1 270 7medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 medinfoEMEA@takeda.com
Malta
 akeda HELLAS S.A.
Tel: +30 210 6387medinfoEMEA@takeda.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 medinfoEMEA@takeda.com</p>
<p>akeda    . .
T : +30 210 6387medinfoEMEA@takeda.com
 sterreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
Espa a
Takeda Farmac utica Espa a S.A.
Tel: +34 917 90 42 medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel.: +48223062medinfoEMEA@takeda.com
France
Takeda France SAS
T l: + 33 1 40 67 33 medinfoEMEA@takeda.com
Portugal
Takeda Farmac uticos Portugal, Lda.
Tel: + 351 21 120 1medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 medinfoEMEA@takeda.com
Rom nia
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska dru ba d.o.o.
Tel: + 386 (0) 59 082 medinfoEMEA@takeda.com
 sland
Vistor hf.
S mi: +354 535 7medinfoEMEA@takeda.com
Slovensk  republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 medinfoEMEA@takeda.com</p>
<p>akeda    . .
 : +30 210 6387medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 medinfoEMEA@takeda.com
This leaflet was last revised in .
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.</p>         </div>"""      



Instance: composition-da-4be09f952ab4cdf2803ef423dc889e5c
InstanceOf: CompositionUvEpi
Title: "Composition for plenadren Package Leaflet"
Description:  "Composition for plenadren Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp4be09f952ab4cdf2803ef423dc889e5c)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - plenadren"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Se den nyeste indlægsseddel på www.indlaegsseddel.dk</p>         </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse
2. Det skal De vide, før De begynder at tage Plenadren
3. Sådan skal De tage Plenadren 
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What plenadren is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What plenadren is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Plenadren indeholder et stof, der kaldes hydrocortison (det kaldes også cortisol). Hydrocortison er et 
glukokortikoid. Det tilhører en gruppe lægemidler, der kaldes kortikosteroider. Glukokortikoider 
forekommer naturligt i kroppen og hjælper med til at opretholde Deres gode helbred og velbefindende. 
Plenadren anvendes til voksne til behandling af en tilstand, der kaldes binyrebarkinsufficiens eller 
cortisolmangel. Binyrebarkinsufficiens optræder, når binyrerne (lige over nyrerne) ikke producerer 
nok af hormonet cortisol. Patienter, der lider af kronisk binyrebarkinsufficiens, har brug for at få en 
substitutionsbehandling for at overleve.
Plenadren erstatter det naturlige cortisol, der mangler hos patienter med binyrebarkinsufficiens. Dette 
lægemiddel sørger for hydrocortison til kroppen hele dagen igennem. Cortisolniveauerne i blodet øges 
hurtigt til et maksimumniveau omkring en time efter indtagelse af tabletten om morgenen, og derefter 
falder niveauet gradvis i løbet af dagen. Sent om aftenen og om natten, når niveauet bør være lavt, er 
der næsten intet cortisol tilbage i blodet.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take plenadren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take plenadren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Tag ikke Plenadren</h2>
<p>hvis De er allergisk over for hydrocortison eller et af de øvrige indholdsstoffer i Plenadren 
(angivet i punkt 6).
Advarsler og forsigtighedsregler
Kontakt lægen eller apotekspersonalet, før De tager Plenadren
-
hvis De har en tilstand, der gør Dem ude af stand til at tage denne medicin, eller hvis medicinen 
ikke bliver absorberet rigtigt i maven. Dette kan være tilfældet, hvis De har maveproblemer, der 
24
omfatter opkastning og/eller diaré. I sådanne situationer bør De omgående søge lægehjælp, så 
De kan få behandling med injektioner af hydrocortison samt få tilført ekstra væske.
-
hvis De har en kortvarende eller forbigående sygdom såsom infektioner eller feber, eller hvis De 
oplever situationer, der giver voldsom fysisk stress som for eksempel kirurgi, skal Deres dosis 
af hydrocortison øges midlertidigt. Bed straks Deres læge om information om, hvordan De skal 
håndtere sådanne situationer. Hvis De skal gennemgå kirurgi, skal De forinden fortælle Deres 
læge/tandlæge, at De tager dette lægemiddel.
-
hvis Deres generelle helbred af en hvilken som helst anden grund bliver dårligere, selv om De 
tager Deres medicin som ordineret; søg omgående lægehjælp.
-
hvis De har fæokromocytom (en sjælden svulst i binyrerne). 
-
hvis Deres skjoldbruskkirtel ikke fungerer normalt, skal De fortælle det til Deres læge, da det 
måske vil være nødvendigt at justere Deres Plenadren-dosis.
Børn og unge
Plenadren bør ikke anvendes hos børn og unge under 18 år, da det ikke er blevet undersøgt hos disse 
patienter.
Brug af andre lægemidler sammen med Plenadren
Fortæl det altid til lægen eller apotekspersonalet, hvis De tager andre lægemidler eller for nylig har
taget andre lægemidler. Under langvarig behandling med lægemidler mod infektioner (antibiotika) vil 
det muligvis være nødvendigt, at Deres læge justerer Deres Plenadren-dosis. Hvis Plenadren anvendes 
sammen med mifepriston, som er et lægemiddel, der anvendes til at afslutte en graviditet, kan 
virkningen af Plenadren blive nedsat.
De bør endvidere fortælle det til lægen eller apotekspersonalet, hvis De bruger et eller flere af 
følgende lægemidler, da det i så fald måske vil være nødvendigt at justere Deres Plenadren-dosis: 

Fenytoin, carbamazepin og barbiturater - anvendes til behandling af epilepsi

Rifampicin eller rifabutin - anvendes til behandling af tuberkulose

Ritonavir, efavirenz og nevirapin - anvendes til behandling af HIV-infektion

Prikbladet perikum - anvendes til behandling af depression og andre tilstande

Ketoconazol, itraconazol, posaconazol og voriconazol - anvendes til behandling af 
svampeinfektioner

Erythromycin, telithromycin og chlarithromycin - anvendes til behandling af bakterieinfektioner
Brug af Plenadren sammen med mad og drikke
Drik ikke grapefrugtjuice, mens De tager Plenadren, da grapefrugtjuice vil forstyrre virkningen af 
dette lægemiddel.
Graviditet, amning og frugtbarhed
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge eller apotekspersonalet til råds, før De tager dette lægemiddel.
Det er vigtigt, at De fortsætter behandlingen med Plenadren under graviditet. Behandling til gravide 
kvinder med binyrebarkinsufficiens vil med sandsynlighed ikke påføre moderen og/eller barnet 
skadelige virkninger. De bør fortælle det til Deres læge, hvis De bliver gravid, da det muligvis vil være 
nødvendigt at justere Deres Plenadren-dosis.
De kan amme under behandlingen med Plenadren. Hydrocortison udskilles i modermælk. Det er 
usandsynligt, at de doser hydrocortison, der anvendes i substitutionsterapi, vil have nogen virkning på 
barnet. De bør dog tale med Deres læge, hvis De planlægger at amme Deres spædbarn.<br />
Frugtbarheden hos kvinder med binyreinsufficiens eller cortisolmangel kan være nedsat. Der er ingen 
indikation for, at Plenadren, i doser, der anvendes i substitutionsterapi, vil have en virkning på 
frugtbarheden.
25
Trafik- og arbejdssikkerhed
Lægemidlet kan i mindre grad påvirke evnen til at føre motorkøretøj og betjene maskiner. Voldsom 
træthed og episoder med kortvarig svimmelhed (vertigo) er indberettet. Dårligt behandlet eller 
ubehandlet binyrebarkinsufficiens nedsætter evnen til at koncentrere sig og vil påvirke evnen til at føre 
motorkøretøj og betjene maskiner. Det er derfor vigtigt, at De tager denne medicin nøjagtigt efter 
lægens anvisning, hvis De skal føre motorkøretøj eller betjene maskiner. Hvis De bliver påvirket af 
medicinen, må De ikke føre motorkøretøj eller betjene maskiner, før De har drøftet emnet med Deres 
læge.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take plenadren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take plenadren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid Plenadren nøjagtigt efter lægens eller apotekspersonalets anvisning. Er De i tvivl, så spørg 
lægen eller apotekspersonalet. Deres dosis er specielt valgt til Dem af Deres læge.

Når De vågner om morgenen, skal De synke Plenadren-tabletten (tabletterne) hele sammen med 
et glas vand mindst 30 minutter, inden De spiser morgenmad; helst mellem kl. 06 og 08 om 
morgenen.

De bør helst være i en oprejst stilling, når De tager Deres medicin.

De må ikke dele, knuse eller tygge tabletterne. Disse tabletter frigiver hydrocortison til kroppen 
hele dagen igennem. Hvis tabletterne deles, knuses eller tygges, kan det forhindre 
hydrocortison-dosen i at dække hele dagen, som den bør.
Behov for yderligere doser Plenadren
Under kortvarig eller forbigående sygdom såsom infektion, feber eller fysisk stress som for eksempel 
kirurgi, vil De have brug for mere hydrocortison, da kroppen ikke kan producere den ekstra mængde 
cortisol, der kræves i sådanne situationer. Deres dosis skal derfor øges midlertidigt, og Deres læge vil 
muligvis råde Dem til at tage andre hydrocortisontabletter i stedet for - eller samtidig med Plenadren. De 
bør drøfte dette med Deres læge og følge lægens anvisninger i, hvorledes De skal handle i sådanne 
situationer.
Det vil muligvis være nødvendigt at fordoble eller tredoble Deres daglige dosis Plenadren i lette 
sygdomstilfælde som for eksempel mild infektion eller stress. De bør da tage den anden dosis af 
lægemidlet 6 til 10 timer efter morgendosen. Hvis det ikke er nok at fordoble den daglige dosis, bør 
De tage en tredje dosis 6 til 10 timer efter den anden dosis (6-10 timers intervaller mellem doserne). 
Når Deres sygdom er ovre, skal De vende tilbage til Deres normale vedligeholdelsesdosis af 
lægemidlet. 
De følgende tegn og symptomer kan tyde på, at De har behov for at tage ekstra doser af Plenadren 
eller andre former for hydrocortison: træthed, vægttab, mavebesvær, følelse af at være omtåget, når De 
rejser Dem op fra siddende stilling, eller svimmelhed, når De står op, mørkere hud, især i hudfolder og 
udsatte områder. Rådfør Dem straks med lægen, hvis De bemærker nogle af disse ting.
De skal imidlertid søge øjeblikkelig lægehjælp, hvis De bemærker noget af følgende: alvorlig 
svaghed, besvimelse, mavesmerter, kvalme, opkastning, rygsmerter, forvirring, nedsat bevidsthed, 
delirium (meget forvirret tilstand). 
Hvis De har taget for meget Plenadren 
En for høj dosis af lægemidlet i mere end nogle få dage kan være skadelig for helbredet. Blodtrykket
kan stige, måske vil De tage på i vægt, og Deres blodsukkerniveau kan blive for højt. En øget dosis er 
nødvendig i særlige tilfælde for at få kroppen til at klare sig i forbindelse med øget stress som for 
eksempel feber. Hvis der ofte og regelmæssigt er behov for ekstra doser, bør De kontakte Deres læge 
og få Deres vedligeholdelsesdosis revurderet.
26
Hvis De har glemt at tage Plenadren
Hvis De har glemt at tage Deres tablet om morgenen, skal De tage den, så snart De kommer i tanker 
om det. De må ikke tage en dobbeltdosis som erstatning for den glemte dosis. Hvis De oplever et eller 
flere af de tegn og symptomer, der er anført i afsnittet "Behov for yderligere doser Plenadren", skal De 
straks kontakte lægen.
Hvis De holder op med at tage Plenadren
At holde op med at tage Plenadren kan være livstruende. Det er derfor vigtigt at fortsætte med at tage 
lægemidlet som ordineret af Deres læge. Hold ikke op med at tage detuden først at have talt med 
Deres læge.
Spørg lægen eller apotekspersonalet, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. 
Hvis De skifter behandling fra andre hydrocortisontabletter til Plenadren, kan De få bivirkninger i 
løbet af de første uger. Disse bivirkninger kan være: ondt i maven, kvalme og træthed. Bivirkningerne 
vil normalt forsvinde i løbet af nogen tid, men hvis de ikke gør det, skal De kontakte Deres læge.
Bivirkninger fra lægemidlet er: 
Meget almindelig (kan påvirke flere end 1 ud af 10 personer)

Svimmelhed

Hovedpine

Diaré

Træthed
Almindelig (kan påvirke op til 1 ud af 10 personer)

Mavepine/halsbrand, kvalme

Ledsmerter

Udslæt

Kløe
Der er indberettet yderligere bivirkninger i forbindelse med andre hydrocortison-lægemidler. Disse 
lægemidler er også givet for andre indikationer end substitutionsterapi ved binyrebarkinsufficiens, og 
ofte i en højere dosis. Hyppigheden af disse mulige bivirkninger er ikke kendt (hyppigheden kan ikke 
estimeres ud fra forhåndenværende data). Tal med lægen, hvis De oplever en af disse bivirkninger:

Mere modtagelig for infektion

Diabetes eller problemer med blodsukkerniveauet (påvist i blodprøver)

Salt- og vandophobning i kroppen, der medfører hævelse og forhøjet blodtryk (påvist ved 
lægeundersøgelse) samt lavt kaliumniveau i blodet

Humørsvingninger såsom en fornemmelse af voldsom ophidselse eller mistet jordforbindelse

Søvnbesvær

Forhøjet tryk i øjet (glaukom), øjets linse bliver sløret (katarakt)

Halsbrand, forværring af eventuelt eksisterende mavesår

Svækkelse af knoglerne - dette kan forårsage knoglebrud

Strækmærker, blå mærker, akne-lignende udslæt, voldsom hårvækst i ansigtet, langsom 
sårheling
27
Indberetning af bivirkninger
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apoteket. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store plenadren"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store plenadren"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. 
Brug ikke lægemidlet efter den udløbsdato, der står på flaskens etiket og æsken efter Exp. 
Udløbsdatoen er den sidste dag i den nævnte måned.
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
Spørg på apoteket, hvordan De skal bortskaffe lægemiddelrester. Af hensyn til miljøet må De ikke 
smide lægemiddelrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Plenadren indeholder:</h2>
<p>Aktivt stof: hydrocortison
Plenadren 5 mg: Hver tablet med modificeret udløsning indeholder 5 mg hydrocortison.
Plenadren 20 mg: Hver tablet med modificeret udløsning indeholder 20 mg hydrocortison.
-
Øvrige indholdsstoffer: hypromellose (E464), mikrokrystallinsk cellulose (E460), 
pregelatiniseret stivelse (majs), vandfri kolloid silica (E551) og magnesiumstearat. 
Belægningen er en blanding af makrogol (3350), polyvinylalkohol, talkum (E553b) og 
titaniumoxid (E171). 5 mg tabletterne indeholder endvidere rød jernoxid (E172), gul jernoxid 
(E172) og sort jernoxid (E172).
Udseende og pakningsstørrelser
Tabletterne med modificeret udløsning er runde (diameter 8 mm) og konvekse.
5 mg tabletterne er lyserøde. 
20 mg tabletterne er hvide. 
Plenadren leveres i flasker med et skruelåg indeholdende 50 tabletter; 
Pakningsstørrelser: 
Karton indeholdende en flaske med 50 tabletter med modificeret udløsning.
Karton indeholdende 2 flasker med 50 tabletter med modificeret udløsning (100 tabletter).
Ikke alle pakningsstørrelser er nødvendigvis markedsført i Deres land. 
Indehaver af markedsføringstilladelsen og fremstiller
Indehaver af markedsføringstilladelsen
Takeda Pharmaceuticals International AG Ireland Branch 
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 HW68
Irland
28
Fremstiller
Takeda Pharmaceuticals International AG Ireland Branch
Block 2 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
D02 HW68
Irland
Shire Pharmaceuticals Ireland
Block 2 &amp; 3 Miesian Plaza
50-58 Baggot Street Lower
Dublin 2
Irland
Hvis De ønsker yderligere oplysninger om dette lægemiddel, skal De henvende Dem til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Takeda Belgium NV
Tél/Tel: +32 2 464 06 medinfoEMEA@takeda.com
Lietuva
Takeda, UAB
Tel: +370 521 09 070
medinfoEMEA@takeda.com
България
Такеда България ЕООД
Тел.: +359 2 958 27 36
medinfoEMEA@takeda.com 
Luxembourg/Luxemburg
Takeda Belgium NV
Tél/Tel: +32 2 464 06 11
medinfoEMEA@takeda.com
Česká republika
Takeda Pharmaceuticals Czech Republic s.r.o.
Tel: +420 234 722 722
medinfoEMEA@takeda.com
Magyarország
Takeda Pharma Kft.
Tel.: +36 1 270 7030
medinfoEMEA@takeda.com
Danmark
Takeda Pharma A/S
Tlf: +45 46 77 10 10
medinfoEMEA@takeda.com
Malta
Τakeda HELLAS S.A.
Tel: +30 210 6387800
medinfoEMEA@takeda.com
Deutschland
Takeda GmbH
Tel: +49 (0)800 825 3325
medinfoEMEA@takeda.com
Nederland
Takeda Nederland B.V.
Tel: +31 20 203 5492
medinfoEMEA@takeda.com
Eesti
Takeda Pharma AS
Tel: +372 6177 669
medinfoEMEA@takeda.com
Norge
Takeda AS
Tlf: +47 800 800 30
medinfoEMEA@takeda.com
Ελλάδα
Τakeda ΕΛΛΑΣ Α.Ε.
Tηλ: +30 210 6387800
medinfoEMEA@takeda.com
Österreich
Takeda Pharma Ges.m.b.H. 
Tel: +43 (0) 800-20 80 medinfoEMEA@takeda.com
España
Takeda Farmacéutica España S.A.
Tel: +34 917 90 42 22
medinfoEMEA@takeda.com
Polska
Takeda Pharma Sp. z o.o.
Tel.: +48223062447
medinfoEMEA@takeda.com
29
France
Takeda France SAS
Tél: + 33 1 40 67 33 00
medinfoEMEA@takeda.com
Portugal
Takeda Farmacêuticos Portugal, Lda.
Tel: + 351 21 120 1457
medinfoEMEA@takeda.com
Hrvatska
Takeda Pharmaceuticals Croatia d.o.o.
Tel: +385 1 377 88 96
medinfoEMEA@takeda.com
România
Takeda Pharmaceuticals SRL
Tel: +40 21 335 03 91
medinfoEMEA@takeda.com
Ireland
Takeda Products Ireland Ltd
Tel: 1800 937 970
medinfoEMEA@takeda.com
Slovenija
Takeda Pharmaceuticals farmacevtska družba d.o.o.
Tel: + 386 (0) 59 082 480
medinfoEMEA@takeda.com
Ísland
Vistor hf.
Sími: +354 535 7000
medinfoEMEA@takeda.com
Slovenská republika
Takeda Pharmaceuticals Slovakia s.r.o.
Tel: +421 (2) 20 602 600
medinfoEMEA@takeda.com
Italia
Takeda Italia S.p.A.
Tel: +39 06 502601
medinfoEMEA@takeda.com
Suomi/Finland
Takeda Oy
Puh/Tel: 0800 774 051
medinfoEMEA@takeda.com
Κύπρος
Τakeda ΕΛΛΑΣ Α.Ε.
Τηλ: +30 210 6387800
medinfoEMEA@takeda.com
Sverige
Takeda Pharma AB
Tel: 020 795 079
medinfoEMEA@takeda.com
Latvija
Takeda Latvia SIA
Tel: +371 67840082
medinfoEMEA@takeda.com
United Kingdom (Northern Ireland)
Takeda UK Ltd
Tel: +44 (0) 2830 640 902
medinfoEMEA@takeda.com
Denne indlægsseddel blev senest ændret .
Andre informationskilder 
De kan finde yderligere oplysninger om Plenadren på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-4be09f952ab4cdf2803ef423dc889e5c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for plenadren Package Leaflet for language en"
Description: "ePI document Bundle for plenadren Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-4be09f952ab4cdf2803ef423dc889e5c"
* entry[0].resource = composition-en-4be09f952ab4cdf2803ef423dc889e5c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4be09f952ab4cdf2803ef423dc889e5c"
* entry[=].resource = mp4be09f952ab4cdf2803ef423dc889e5c
                            
                    
Instance: bundlepackageleaflet-da-4be09f952ab4cdf2803ef423dc889e5c
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for plenadren Package Leaflet for language da"
Description: "ePI document Bundle for plenadren Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-4be09f952ab4cdf2803ef423dc889e5c"
* entry[0].resource = composition-da-4be09f952ab4cdf2803ef423dc889e5c

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp4be09f952ab4cdf2803ef423dc889e5c"
* entry[=].resource = mp4be09f952ab4cdf2803ef423dc889e5c
                            
                    



Instance: mp4be09f952ab4cdf2803ef423dc889e5c
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Plenadren 5 mg modified-release tablets"
Description: "Plenadren 5 mg modified-release tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Plenadren 5 mg modified-release tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Plenadren 5 mg modified-release tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 4be09f952ab4cdf2803ef423dc889e5cListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "plenadren"

* status = #current
* mode = #working

* title = "List of all ePIs associated with plenadren"

* subject = Reference(mp4be09f952ab4cdf2803ef423dc889e5c)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#plenadren "plenadren"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-4be09f952ab4cdf2803ef423dc889e5c) // plenadren en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-4be09f952ab4cdf2803ef423dc889e5c) // plenadren da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-4be09f952ab4cdf2803ef423dc889e5c
InstanceOf: List

* insert 4be09f952ab4cdf2803ef423dc889e5cListRuleset
    